Oncopeptides (Sweden)

Recent papers from Oncopeptides (Sweden)

1. UH-CAN Lung: Urine Home Collection for Lung Cancer Risk Assessment in Lung Cancer Screening Non-Responders – an observational, feasibility study protocolF1000Research · 2026
2. Abstract 1598: Preclinical efficacy of a bispecific NK cell engager studied using a humanized multiple myeloma mouse modelCancer Research · 2026
3. Efficacy of melflufen in multiple myeloma with mutated or deleted TP53Experimental Hematology and Oncology · 2025
4. Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myelomaBlood · 2025
5. Cellular Diversity, Immune Crosstalk, and Genomic Alterations in Light Chain Amyloidosis2025
6. An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple MyelomaInternational Journal of Molecular Sciences · 2025
7. External Validation of Plasma Glycosaminoglycans as Biomarkers to Improve Lung Cancer Risk StratificationCancer Epidemiology Biomarkers & Prevention · 2025
8. Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted TP532024
9. Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomes2024
10. Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN studyHaematologica · 2024
11. PORT: A Randomized, Cross-over, Phase 2 Study of Melflufen Peripheral versus Central Intravenous Administration in Patients with Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma & Leukemia · 2024
12. Green Chemistry Articles of Interest to the Pharmaceutical IndustryOrganic Process Research & Development · 2024
13. 18 F-labelling of nitrogen-containing aryl boronates – anti-cancer drug melflufen as a case studyOrganic Chemistry Frontiers · 2024
14. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN studyEuropean Journal Of Haematology · 2023
15. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE studyHaematologica · 2023
16. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa studyHaematologica · 2023
17. Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON StudiesClinical Lymphoma Myeloma & Leukemia · 2023
18. P34 Lighthouse (Op-108): Melflufen Plus Daratumumab (Dara) and Dexamethasone (Dex) Versus Dara in Relapsed/Refractory Multiple Myeloma (Rrmm) Refractory to an Immunomodulatory Drug (Imid) and a Proteasome Inhibitor (Pi) or Had Received ≥3 Prior Lines of Therapy Including an Imid and a PiHemaSphere · 2023
19. A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of actionBiochemical and Biophysical Research Communications · 2023
20. Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug MelflufenTyöväentutkimus Vuosikirja · 2022